{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T10:01:56Z","timestamp":1790416916973,"version":"4.1.0"},"reference-count":28,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2015,9,1]],"date-time":"2015-09-01T00:00:00Z","timestamp":1441065600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2015,6,23]],"date-time":"2015-06-23T00:00:00Z","timestamp":1435017600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","valueinhealthjournal.com","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Value in Health"],"published-print":{"date-parts":[[2015,9]]},"DOI":"10.1016\/j.jval.2015.05.003","type":"journal-article","created":{"date-parts":[[2015,8,13]],"date-time":"2015-08-13T15:52:03Z","timestamp":1439481123000},"page":"865-875","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":23,"title":["Unifying Research and Reimbursement Decisions: Case Studies Demonstrating the Sequence of Assessment and Judgments Required"],"prefix":"10.1016","volume":"18","author":[{"given":"Claire","family":"McKenna","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marta","family":"Soares","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karl","family":"Claxton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Bojke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susan","family":"Griffin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen","family":"Palmer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eldon","family":"Spackman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jval.2015.05.003_bib1","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1016\/S0167-6296(98)00039-3","article-title":"The irrelevance of inference: a decision-making approach to the stochastic evaluation of health care technologies","volume":"18","author":"Claxton","year":"1999","journal-title":"J Health Econ"},{"key":"10.1016\/j.jval.2015.05.003_bib2","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1377\/hlthaff.24.1.93","article-title":"When is evidence sufficient?","volume":"24","author":"Claxton","year":"2005","journal-title":"Health Aff"},{"key":"10.1016\/j.jval.2015.05.003_bib3","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1016\/S0140-6736(02)09832-X","article-title":"A rational framework for decision making by the National Institute for Clinical Excellence","volume":"360","author":"Claxton","year":"2002","journal-title":"Lancet"},{"key":"10.1016\/j.jval.2015.05.003_bib4","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1002\/hec.1586","article-title":"Dangerous omissions: the consequences of ignoring decision uncertainty","volume":"20","author":"Griffin","year":"2011","journal-title":"Health Econ"},{"key":"10.1016\/j.jval.2015.05.003_bib5","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1017\/S0266462309990882","article-title":"Coverage with evidence development: applications and issues","volume":"26","author":"Trueman","year":"2010","journal-title":"Int J Technol Assess Health Care"},{"key":"10.1016\/j.jval.2015.05.003_bib6","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1177\/0272989X07312724","article-title":"The half-life of truth: what are appropriate time horizons for research decisions?","volume":"28","author":"Philips","year":"2008","journal-title":"Med Decis Making"},{"key":"10.1016\/j.jval.2015.05.003_bib7","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1111\/j.1524-4733.2007.00296.x","article-title":"Time and expected value of sample information wait for no patient","volume":"11","author":"Eckermann","year":"2008","journal-title":"Value Health"},{"key":"10.1016\/j.jval.2015.05.003_bib8","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1177\/0272989X07312477","article-title":"The option value of delay in health technology assessment","volume":"28","author":"Eckermann","year":"2008","journal-title":"Med Decis Making"},{"key":"10.1016\/j.jval.2015.05.003_bib9","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1177\/0272989X11399921","article-title":"Addressing adoption and research design decisions simultaneously: the role of value of sample information analysis","volume":"31","author":"McKenna","year":"2011","journal-title":"Med Decis Making"},{"key":"10.1016\/j.jval.2015.05.003_bib10","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3310\/hta16460","article-title":"Informing a decision framework for when NICE should recommend the use of health technologies only in the context of an appropriately designed programme of evidence development","volume":"16","author":"Claxton","year":"2012","journal-title":"Health Technol Assess"},{"key":"10.1016\/j.jval.2015.05.003_bib11","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3310\/hta8400","article-title":"Clopidogrel used in combination with aspirin compared with aspirin alone in the treatment of non-ST-segment elevation acute coronary syndromes: a systematic review and economic evaluation","volume":"8","author":"Main","year":"2004","journal-title":"Health Technol Assess"},{"key":"10.1016\/j.jval.2015.05.003_bib12","doi-asserted-by":"crossref","DOI":"10.3310\/hta13240","article-title":"Enhanced external counterpulsation for the treatment of stable angina and heart failure: a systematic review and economic analysis","volume":"13","author":"McKenna","year":"2009","journal-title":"Health Technol Assess"},{"key":"10.1016\/j.jval.2015.05.003_bib13","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3310\/hta13310","article-title":"The effect of different treatment durations of clopidogrel in patients with non-ST-segment elevation acute coronary syndromes: a systematic review and value of information analysis","volume":"13","author":"Rogowski","year":"2009","journal-title":"Health Technol Assess"},{"key":"10.1016\/j.jval.2015.05.003_bib14","unstructured":"TA80: Clopidogrel in the Treatment of Non-ST-Segment-Elevation Acute Coronary Syndrome. London: National Institute for Health and Clinical Excellence, 2004."},{"key":"10.1016\/j.jval.2015.05.003_bib15","unstructured":"CG94: Unstable Angina and NSTEMI: The Early Management of Unstable Angina and Non-ST-Segment-Elevation Myocardial Infarction. London: National Institute for Health and Clinical Excellence, 2010."},{"key":"10.1016\/j.jval.2015.05.003_bib16","unstructured":"Claxton K, Palmer S, Longworth L, et al. Uncertainty, evidence and irrecoverable costs: informing approval, pricing and research decisions for health technologies. Centre for Health Economics, University of York, CHE Research Paper 69, 2011."},{"key":"10.1016\/j.jval.2015.05.003_bib17","unstructured":"Guide to the Methods of Technology Appraisal. London: National Institute for Health and Clinical Excellence, 2008."},{"key":"10.1016\/j.jval.2015.05.003_bib18","series-title":"Morbidity: Coronary Heart Disease Statistics","author":"Allender","year":"2007"},{"key":"10.1016\/j.jval.2015.05.003_bib19","unstructured":"Claxton K, Eggington S, Ginnelly L, et al. A pilot study of value of information analysis to support research recommendations for the National Institute for Clinical Excellence. Centre for Health Economics, York, Research Paper 4, 2005."},{"key":"10.1016\/j.jval.2015.05.003_bib20","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.2165\/00019053-200624110-00003","article-title":"Using value of information analysis to prioritise health research: some lessons from recent UK experience","volume":"24","author":"Claxton","year":"2006","journal-title":"Pharmacoeconomics"},{"key":"10.1016\/j.jval.2015.05.003_bib21","first-page":"30981","article-title":"Medicare and Medicaid programs: conditions for coverage for organ procurement organizations (OPOs)","volume":"31","year":"2006","journal-title":"Final rule. Fed Reg"},{"key":"10.1016\/j.jval.2015.05.003_bib22","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1258\/jrsm.100.10.453","article-title":"Making a decision to wait for more evidence: when the National Institute for Health and Clinical Excellence recommends a technology only in the context of research","volume":"100","author":"Chalkidou","year":"2007","journal-title":"J Royal Soc Med"},{"key":"10.1016\/j.jval.2015.05.003_bib23","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1016\/j.healthpol.2010.02.005","article-title":"Linking payment to health outcomes: a taxonomy and examination of performance-based reimbursement schemes between healthcare payers and manufacturers","volume":"96","author":"Carlson","year":"2010","journal-title":"Health Policy"},{"key":"10.1016\/j.jval.2015.05.003_bib24","doi-asserted-by":"crossref","first-page":"143","DOI":"10.2165\/11530850-000000000-00000","article-title":"Access with evidence development schemes: a framework for description and evaluation","volume":"28","author":"McCabe","year":"2010","journal-title":"Pharmacoeconomics"},{"key":"10.1016\/j.jval.2015.05.003_bib25","doi-asserted-by":"crossref","first-page":"113","DOI":"10.2165\/11530820-000000000-00000","article-title":"Funding the unfundable: mechanisms for managing uncertainty in decisions on the introduction of new and innovative technologies into healthcare systems","volume":"28","author":"Stafinski","year":"2010","journal-title":"Pharmacoeconomics"},{"key":"10.1016\/j.jval.2015.05.003_bib26","doi-asserted-by":"crossref","first-page":"93","DOI":"10.2165\/11314080-000000000-00000","article-title":"Can\u2019t get no satisfaction? Will pay for performance help? Toward an economic framework for understanding performance-based risk-sharing agreements for innovative medical products","volume":"28","author":"Towse","year":"2010","journal-title":"Pharmacoeconomics"},{"key":"10.1016\/j.jval.2015.05.003_bib27","series-title":"Linking payment and health outcomes: a systematic review of performance-based health","author":"Carlson","year":"2008"},{"key":"10.1016\/j.jval.2015.05.003_bib28","article-title":"Expected health benefits of additional evidence: principles, methods and applications","volume":"Paper 83","author":"Claxton","year":"2013","journal-title":"Centre for Health Economics, University of York, CHE Research"}],"container-title":["Value in Health"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1098301515019646?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1098301515019646?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,9,20]],"date-time":"2018-09-20T07:29:00Z","timestamp":1537428540000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1098301515019646"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,9]]},"references-count":28,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2015,9]]}},"alternative-id":["S1098301515019646"],"URL":"https:\/\/doi.org\/10.1016\/j.jval.2015.05.003","relation":{},"ISSN":["1098-3015"],"issn-type":[{"value":"1098-3015","type":"print"}],"subject":[],"published":{"date-parts":[[2015,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Unifying Research and Reimbursement Decisions: Case Studies Demonstrating the Sequence of Assessment and Judgments Required","name":"articletitle","label":"Article Title"},{"value":"Value in Health","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jval.2015.05.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2015 International Society for Pharmacoeconomics and Outcomes Research (ISPOR). Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}